⇚ Regimen OPDIVO® and YERVOY® with Limited Course Chemotherapy - for Non Small Cell Lung Cancer (Adenocarcinoma) Medical Name OPDIVO® (Nivolumab) and YERVOY® (Ipilimumab) with 2 cycles of ALIMTA® (Pemetrexed) and PARAPLATIN® (Carboplatin) - for advanced NSCLC Cycles Given N/A Delivery Phases N/A Special Instructions Chemotherapy with ALIMTA® and PARAPLATIN® is for 2 cycles only, for rapid disease control of Lung Cancer with adenocarcinoma histology. Both OPDIVO® and YERVOY® are administered for 2 years or until disease progression or unacceptable toxicity. Monitor closely for immune mediated end organ damage such as Pneumonitis, Colitis, Hepatitis, Nephritis and Endocrinopathies. References Reck M, et al. ASCO Meeting 2020 - VIEW Drug Mode Given Standard Dose Days to Be Given Frequency Solution Volume Duration OPDIVO® (Nivolumab) IV 360 mg D1 q21 NSS 250 cc 60 minutes YERVOY® (Ipilimumab) IV 1 mg/kg D1 q42 NSS 250 cc 60 minutes ALIMTA® (Pemetrexed) IV 500 mg/m2 D1 q21 NSS 100 cc 15 minutes PARAPLATIN® (Carboplatin) IV AUC 5 D1 q21 NSS 250 cc 60 minutes